LCZ696(Sacubitril + Valsartan)
wehewehe
ʻO LCZ696 (Sacubitril/Valsartan), ʻo Valsartan (he ARB) a me Sacubitril (AHU377) i ka ratio molar 1:1, he mea mua i loko o ka papa, bioavailable waha, a me ka hana ʻelua angiotensin receptor-neprilysin (ARN) inhibitor no ka hypertension. a me ka puʻuwai puʻuwai[1][2][3].Hoʻomaikaʻi ʻo LCZ696 i ka cardiomyopathy maʻi maʻi ma o ke kāohi ʻana i ka mumū, ke kaumaha oxidative a me ka apoptosis.
Ka hope
ʻO ka LCZ696 ka mea mua ma ka papa ARNi (angiotensin receptor neprilysin inhibitor) e komo ana i nā moieties anionic o AR valsartan a me ka neprilysin inhibitor prodrug AHU377 (1:1 ratio) no ka hāʻule o ka naʻau a me ke kiʻekiʻe.
ʻO nā mea i loaʻa i ka angiotensin he mau mea hoʻokipa G-protein-coupled.Hoʻopili lākou i ka cardiovascular a me nā hopena ʻē aʻe o ka angiotensin II kahi peptide bioactive o ka ʻōnaehana renin-angiotensin.ʻO Neprilysin kahi endopeptidase kūʻokoʻa e hoʻohaʻahaʻa i nā peptides vasoactive endogenous e like me nā peptides natriuretic.ʻO ka hoʻopaʻa ʻana i ka neprilysin e hoʻonui i ka natriuretic peptides kaila i kōkua i ka mālama ʻana i ka naʻau, vascular a me ka renal.[1]
I nā ʻiole Sprague-Dawley, alakaʻi ka hoʻokele waha o LCZ696 i ka piʻi ʻana o ka nui o ka immunoreactivity o ka peptide natriuretic atrial i hopena mai ka neprilysin inhibition.I loko o nā ʻiole transgenic pālua hypertensive, LCZ696 ka mea i hoʻemi ʻia ka nui o ke kaomi arterial mean.ʻO ka poʻe i komo i ke olakino, kahi haʻawina i hoʻopaʻa ʻia, pālua-makapō, placebo-controlled study ua hoʻolako ʻo LCZ696 i ka concurrent neprilysin inhibition a me AT1 receptor blockade.Ua palekana a ʻae ʻia ka LCZ696 i ke kanaka.[2] [3]
Kuhikuhi:
McMurray JJ, Packer M, Desai AS et al.ʻO ka Angiotensin-neprilysin inhibition versus enalapril i ka pau ʻole o ka naʻau.N Engl J Med.2014 Sep 11;371(11):993-1004.
Gu J, Noe A, Chandra P, Al-Fayoumi S et al.ʻO Pharmacokinetics a me ka lāʻau lapaʻau o LCZ696, kahi moʻolelo dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).J Clin Pharmacol.2010 Apr;50(4):401-14.
Langenickel TH, Dole WP.ʻO ka Angiotensin receptor-neprilysin inhibition me LCZ696: kahi ala hou no ka mālama ʻana i ka hemahema o ka naʻau, Drug Discov Today: Ther Strategies (2014),
Waihona
| Pauda | -20°C | 3 makahiki |
| 4°C | 2 makahiki | |
| I ka solvent | -80°C | 6 mahina |
| -20°C | 1 mahina |
ʻO ke kinona
Manaʻo18Nā papahana Loiloi Kūlike Kūlike i ʻae ʻia4, a6nā papahana ma lalo o ka ʻae ʻia.
Ua hoʻokumu ka ʻōnaehana hoʻokele maikaʻi honua kiʻekiʻe i ke kumu kūʻai.
Holo ka nānā ʻana i ka maikaʻi ma ke ola holoʻokoʻa o ka huahana e hōʻoia i ka maikaʻi a me ka hopena therapeutic.
Kākoʻo ka hui ʻoihana Regulatory Affairs i nā koi maikaʻi i ka wā o ke noi a me ke kau inoa ʻana.
Kolea Countec Bottled Packaging Line
ʻO Taiwan CVC Bottled Packaging Line
ʻO Italia CAM Board Packaging Line
Mekini Fette Compacting German
ʻO Iapana Viswill Tablet ʻIke
Keena Mana DCS
